Pain is common among patients with IIMs and is linked to worse physical function, increased fatigue, and reduced quality of life.

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Objective To elucidate the common and distinct clinical features of immune-mediated necrotising myopathy (IMNM), also known as necrotising autoimmune myopathy associated with autoantibodies against ...

Background Statin-induced immune mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. This ...

Key Highlights: Overall, 10 patients have been treated with C-CAR168 including 7 LN patients, 1 Secondary Progressive Multiple Sclerosis (SPMS), 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) and 1 ...

Anti-hydroxy-3-methylglutaryl-coenzyme A reductase represents an infrequent immune-mediated necrotising myopathy. This case study involves a 55-year-old African American woman experiencing muscle ...

Immune-mediated necrotizing myopathies present with symptoms similar to those of other idiopathic inflammatory myopathies, but the muscle biopsy demonstrates necrosis of muscle fibers, as opposed ...

It is also under development for the treatment of myasthenia gravis, primary membranous nephropathy, idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis ...

It is also under development for the treatment of myasthenia gravis, primary membranous nephropathy, idiopathic inflammatory myopathy (IIM), anti-neutrophil cytoplasmic antibody-associated vasculitis ...

The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of idiopathic inflammatory myopathies (IIM ...